Literature DB >> 23729323

Specifications of a continual reassessment method design for phase I trials of combined drugs.

Nolan A Wages1, Mark R Conaway.   

Abstract

In studies of combinations of agents in phase I oncology trials, the dose-toxicity relationship may not be monotone for all combinations, in which case the toxicity probabilities follow a partial order. The continual reassessment method for partial orders (PO-CRM) is a design for phase I trials of combinations that leans upon identifying possible complete orders associated with the partial order. This article addresses some practical design considerations not previously undertaken when describing the PO-CRM. We describe an approach in choosing a proper subset of possible orderings, formulated according to the known toxicity relationships within a matrix of combination therapies. Other design issues, such as working model selection and stopping rules, are also discussed. We demonstrate the practical ability of PO-CRM as a phase I design for combinations through its use in a recent trial designed at the University of Virginia Cancer Center.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  continual reassessment method; dose finding; drug combination; maximum tolerated dose; partial ordering; phase I trials

Mesh:

Year:  2013        PMID: 23729323      PMCID: PMC3771354          DOI: 10.1002/pst.1575

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  14 in total

1.  Non-parametric optimal design in dose finding studies.

Authors:  John O'Quigley; Xavier Paoletti; Jean Maccario
Journal:  Biostatistics       Date:  2002-03       Impact factor: 5.899

2.  Designs for single- or multiple-agent phase I trials.

Authors:  Mark R Conaway; Stephanie Dunbar; Shyamal D Peddada
Journal:  Biometrics       Date:  2004-09       Impact factor: 2.571

3.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

4.  Using the time-to-event continual reassessment method in the presence of partial orders.

Authors:  Nolan A Wages; Mark R Conaway; John O'Quigley
Journal:  Stat Med       Date:  2012-07-17       Impact factor: 2.373

5.  A comparison of two phase I trial designs.

Authors:  E L Korn; D Midthune; T T Chen; L V Rubinstein; M C Christian; R M Simon
Journal:  Stat Med       Date:  1994-09-30       Impact factor: 2.373

6.  Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.

Authors:  A Patnaik; E Warner; M Michael; M J Egorin; M J Moore; L L Siu; P M Fracasso; S Rivkin; I Kerr; M Litchman; A M Oza
Journal:  J Clin Oncol       Date:  2000-11-01       Impact factor: 44.544

7.  Continual reassessment method for partial ordering.

Authors:  Nolan A Wages; Mark R Conaway; John O'Quigley
Journal:  Biometrics       Date:  2011-03-01       Impact factor: 2.571

8.  A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.

Authors:  James R Berenson; Ori Yellin; Ravi Patel; Herb Duvivier; Youram Nassir; Russell Mapes; Christina DiLauro Abaya; Regina A Swift
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

9.  Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.

Authors:  Malcolm Ranson; Mark R Middleton; John Bridgewater; Siow Ming Lee; Martin Dawson; Debra Jowle; Gavin Halbert; Sue Waller; Helen McGrath; Lindsey Gumbrell; R Stanley McElhinney; Dorothy Donnelly; T Brian H McMurry; Geoffrey P Margison
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

10.  Model calibration in the continual reassessment method.

Authors:  Shing M Lee
Journal:  Clin Trials       Date:  2009-06       Impact factor: 2.486

View more
  10 in total

1.  A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.

Authors:  Akihiro Hirakawa; Nolan A Wages; Hiroyuki Sato; Shigeyuki Matsui
Journal:  Stat Med       Date:  2015-05-13       Impact factor: 2.373

2.  Phase I design for completely or partially ordered treatment schedules.

Authors:  Nolan A Wages; John O'Quigley; Mark R Conaway
Journal:  Stat Med       Date:  2013-09-30       Impact factor: 2.373

Review 3.  Practical designs for Phase I combination studies in oncology.

Authors:  Nolan A Wages; Anastasia Ivanova; Olga Marchenko
Journal:  J Biopharm Stat       Date:  2016       Impact factor: 1.051

4.  A design for phase I trials in completely or partially ordered groups.

Authors:  Mark R Conaway
Journal:  Stat Med       Date:  2017-04-06       Impact factor: 2.373

5.  Comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, S. Zohar.

Authors:  Nolan A Wages
Journal:  Stat Med       Date:  2015-01-15       Impact factor: 2.373

6.  Designs for phase I trials in ordered groups.

Authors:  Mark R Conaway; Nolan A Wages
Journal:  Stat Med       Date:  2016-09-14       Impact factor: 2.373

7.  pocrm: an R-package for phase I trials of combinations of agents.

Authors:  Nolan A Wages; Nikole Varhegyi
Journal:  Comput Methods Programs Biomed       Date:  2013-07-18       Impact factor: 5.428

8.  Phase I/II adaptive design for drug combination oncology trials.

Authors:  Nolan A Wages; Mark R Conaway
Journal:  Stat Med       Date:  2014-01-28       Impact factor: 2.373

9.  A surface-free design for phase I dual-agent combination trials.

Authors:  Pavel Mozgunov; Mauro Gasparini; Thomas Jaki
Journal:  Stat Methods Med Res       Date:  2020-04-27       Impact factor: 3.021

10.  A benchmark for dose-finding studies with unknown ordering.

Authors:  Pavel Mozgunov; Xavier Paoletti; Thomas Jaki
Journal:  Biostatistics       Date:  2022-07-18       Impact factor: 5.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.